A. Polk

发表

Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer

K. Vistisen, M. Schou, F. Larsen, 2016, BMJ Open.

Reliability of patient-reported functional outcome in a joint replacement registry

S. Brorson, B. Olsen, J. Rasmussen, 2013, Acta orthopaedica.

Outcome, revision rate and indication for revision following resurfacing hemiarthroplasty for osteoarthritis of the shoulder: 837 operations reported to the Danish Shoulder Arthroplasty Registry.

S. Brorson, B. Olsen, J. Rasmussen, 2014, The bone & joint journal.

Cardiotoxicity in Asymptomatic Patients Receiving Adjuvant 5-fluorouracil

K. Vistisen, D. Nielsen, K. Nielsen, 2014 .

Patient-reported outcome and risk of revision after shoulder replacement for osteoarthritis

S. Brorson, B. Olsen, J. Rasmussen, 2014, Acta orthopaedica.

Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.

Kirsten Vistisen, K. Vistisen, Anne Polk, 2013, Cancer treatment reviews.

A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity

K. Vistisen, M. Vaage-Nilsen, D. Nielsen, 2014, BMC Pharmacology and Toxicology.

Checkpoint inhibitors in breast cancer - Current status.

I. Svane, M. Andersson, D. Nielsen, 2018, Cancer treatment reviews.

Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.

D. Nielsen, F. Larsen, A. Polk, 2018, Cancer treatment reviews.

Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence

I. Kümler, Iben Kümler, Anne Polk, 2016, ESMO Open.

Incidence and risk factors for capecitabine-induced symptomatic cardiotoxicity: a retrospective study of 452 consecutive patients with metastatic breast cancer

K. Vistisen, M. Schou, F. Larsen, 2016, BMJ Open.